A sirolimus-coated balloon (SCB) strategy was noninferior to an everolimus-eluting stent (EES) for target-lesion failure (TLF) at 12 months in patients with successfully prepared de novo native coronary lesions, according to late-breaking data from the TRANSFORM II trial.